Literature DB >> 25270552

Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells.

Xin-Hui Qi1, Di Wu1, Hui-Xia Cui1, Nan Ma1, Jia Su1, Yu-Tong Wang1, You-Hong Jiang1.   

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death in the world. The gene glypican-3 (GPC3) is reported to be a potential therapeutic target for HCC. In this study, we use RNA interference with lentiviral vectors to explore the effect of GPC3 silencing on the biological behavior of HCC cells and the potential role of the GPC3 protein in the activation of epithelial-mesenchymal transition (EMT), which relates to HCC cell invasion and migration. Our data suggest that GPC3 silencing leads to a decrease in HCC cell proliferation and to an increase in apoptosis. We demonstrated that GPC3 silencing regulates cell invasion and migration, most probably through the activation of the EMT cellular program. In conclusion, GPC3 is associated with the HCC cell biological behavior, while the relationship between GPC3 and EMT in tumorigenesis of HCC deserves future investigation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25270552     DOI: 10.3892/mmr.2014.2600

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  11 in total

1.  Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma.

Authors:  Youcai Li; Jun Zhang; Jiamei Gu; Kongzhen Hu; Shun Huang; Peter S Conti; Hubing Wu; Kai Chen
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

2.  Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells.

Authors:  Ying Liu; Dongping Zheng; Mingming Liu; Jiao Bai; Xi Zhou; Baolan Gong; Jieyu Lü; Yi Zhang; Hui Huang; Wenying Luo; Guangrong Huang
Journal:  Tumour Biol       Date:  2015-05-14

3.  Enhanced specific antitumor immunity of dendritic cells transduced with the glypican 3 gene and co-cultured with cytokine-induced killer cells against hepatocellular carcinoma cells.

Authors:  Yuliang Wang; Yinlong Wang; Hong Mu; Tao Liu; Xiaobo Chen; Zhongyang Shen
Journal:  Mol Med Rep       Date:  2015-01-22       Impact factor: 2.952

4.  KLHL21, a novel gene that contributes to the progression of hepatocellular carcinoma.

Authors:  Lei Shi; Wenfa Zhang; Fagui Zou; Lihua Mei; Gang Wu; Yong Teng
Journal:  BMC Cancer       Date:  2016-10-21       Impact factor: 4.430

5.  Glypican-3 Expression in Patients with Oral Squamous Cell Carcinoma.

Authors:  Azadeh Andisheh-Tadbir; Amir Saeed Goharian; Mohammad Ali Ranjbar
Journal:  J Dent (Shiraz)       Date:  2020-06

Review 6.  Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma.

Authors:  Meng Guo; Hailing Zhang; Jianming Zheng; Yangfang Liu
Journal:  J Cancer       Date:  2020-02-03       Impact factor: 4.207

7.  Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy.

Authors:  Wei Dong; Kai Yan; Hua Yu; Lei Huo; Zhihong Xian; Yanqing Zhao; Jutang Li; Yuchan Zhang; Zhenying Cao; Yong Fu; Wenming Cong; Hui Dong
Journal:  Front Oncol       Date:  2021-02-11       Impact factor: 6.244

8.  Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma.

Authors:  Tsung-Chieh Shih; Lijun Wang; Hsiao-Chi Wang; Yu-Jui Yvonne Wan
Journal:  Liver Res       Date:  2020-11-11

9.  Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells.

Authors:  Lilian Fedra Castillo; Rocío Tascón; María Amparo Lago Huvelle; Gisela Novack; María Candelaria Llorens; Ancely Ferreira Dos Santos; Jorge Shortrede; Ana María Cabanillas; Elisa Bal de Kier Joffé; Leticia Labriola; María Giselle Peters
Journal:  Oncotarget       Date:  2016-09-13

10.  Cobalt Chloride Induced Apoptosis by Inhibiting GPC3 Expression via the HIF-1α/c-Myc Axis in HepG2 Cells.

Authors:  Yaoyao Tong; Kun Tong; Qinghong Zhu; Yuqin Wu; Yi Yang; Jicai Zhang; Pei Hu; Shirong Yan
Journal:  Onco Targets Ther       Date:  2019-12-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.